Targeted cancer therapies: The future of cancer treatment

Acta Biomedica

Volumn 83, Issue 3, 2012, Pages 220-233

  Kumar, Manoj ^a   Nagpal, Ravinder ^b   Hemalatha, R ^a   Verma, Vinod ^c   Kumar, Ashok ^d   Singh, Satvinder ^e   Marotta, Francesco ^f   Jain, Shalini ^g   Yadav, Hariom ^g  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c DEPARTMENT OF CARDIOLOGY   (Singapore)

^d MLKPG College   (India)

^e NATIONAL DAIRY RESEARCH INSTITUTE   (India)

^f ReGenera Research Group for Aging Intervention   (Italy)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Anticancer therapy; Antitumor drugs; Cancer prescription; Cancer treatments

Indexed keywords

ALEMTUZUMAB; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; FLUOROURACIL; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IMATINIB; IMC C 225; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; RALTITREXED; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VIRUS VECTOR;

ADJUVANT THERAPY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER THERAPY; CAPILLARY LEAK SYNDROME; CELL DIVISION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GRAFT REJECTION; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NANOTECHNOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; SIDE EFFECT; T CELL LYMPHOMA; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASMS; PHYTOTHERAPY;

EID: 84879713633     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist 2007; 12: 443-50.
2. Rivory LP. New drugs for colorectal cancer: mechanisms of action. Australian Prescriber 2002; 25: 108-110.
3. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002; 38: S3-S10.
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
5. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265: 7709-7712.
6. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-365.
7. th ed.) 2008. London: Cmp United Business Media; Chapter 3, pp 1-9.
8. Gambacorti-Passerini C, Gunby R, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Ph-positive leukemias. Lancet Oncology 2003; 4: 75-85.
9. Deininger M, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with Imatinib. Pharmacol Rev 2003; 55: 401-23.
10. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-34.
11. Pao W, Miller V, Zakowski M. EGF receptor gene mutations are common in lung cancers from"never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101 (36): 13306-11
12. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004; 305: 1163-7.
13. Raymond E, Faivre S, Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60: 15-23.
14. Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007; 21: 838-42.
15. Jordan VC. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993; 110: 507-17.
16. Cancer Research UK. "Breast cancer in men". CancerHelp UK. 2007-09-28. http://www.cancerhelp.org.uk
17. Center for Drug Evaluation and Research (03/08/2005). Tamoxifen Information: reducing the incidence of breast cancer in women at high risk. U.S. Food and Drug Administration. http://www.fda.gov/cder/news/tamoxifen/
18. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-75.
19. Wang DY, Fulthorpe R, Liss SN, Edwards EA. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 2004; 18: 402-11.
20. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843-52.
21. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68: 826-33.
22. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456: 663-6.
23. Osborne CK, Bardou V, Hopp TA, Chamness GC, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-61.
24. www.modernmedicine.com (2008). New Mechanism Predicts Tamoxifen Response: PAX2 gene implicated in tamoxifen-induced inhibition of ERBB2/HER2-mediated tumor growth.
25. CORDIS News. 2008-11-14. Study sheds new light on tamoxifen resistance. http://cordis.europa.eu
26. Old LJ. Immunotherapy for cancer. Sci Am 1996; 275: 136-43.
27. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000; 26: 269-86.
28. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009; 27: 663-71.
29. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009; 360: 1408-17.
30. Schrag, D. The price tag on progress: chemotherapy for colorectal cancer. New England J Med 2004; 351: 317-9.
31. Shaw T, Quan J, Totoritis M. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003; 62: ii55-ii59.
32. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108: 1975-8.
33. Hudis, CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
34. Bange, J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nature Medicine 2001;7: 548-52.
35. Menard, S; Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-8.
36. Kute T, Lack CM, Willingham M, et al. Development of herceptin resistance in breast cancer cells. Cytometry 2004, 57A: 86-93.
37. www.nature.com/nature/journal/v421/n6924/full/nature01392.html
38. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. "Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4". Advances in Experimental Medicine and Biology2003; 532: 253-68.
39. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
40. Avastin Prescribing Information, Genentech Inc., October 2006. www.clinicaltrials.gov
41. F.D.A. Approves Drug's Use for Breast Cancer. The New York Times. February 22, 2008. http://www.nytimes.com/ 2008/02/22/business/apee-drug.html.
42. Reed K. Roche drug Avastin fails cancer study, shares fall. Reuters 2009 (April, 22), Zurich.
43. Berkow R, Beers MH. Cancer and the immune system. In: The Merck Manual of Medical Information. Whitehouse Station, NJ; Merck Research Laboratories 1997: 792-4.
44. Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Falcoff E, Schwab D. Treatment of metastatic melanoma with recombinant interferon alfa-2b. Invest New Drugs 1987; 5: S61-S63.
45. Sertoli MR, Bernengo MG, Ardizzoni A, et al. Phase II trial of recombinant alfa-2b interferon in the treatment of metastatic skin melanoma. Oncology 1989; 46: 96-8.
46. Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in outpatients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Ann Oncol 1996; 7: 525-8.
47. Lissoni P, Barni S, Tancini G, et al. Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Arch Ital Urol Androl 1997; 69: 41-7.
48. Atkins MB, Roberston MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-17.
49. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19: 3836-47.
50. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factorsecreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-56.
51. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in gliobastoma multiforme. J Neurooncol 2001; 53: 39-46.
52. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001; 19: 2576-82.
53. Hsueh EC, Famatiga E, Gupta RK, Qi K, Morton DL. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann Surg Oncol 1998; 5: 595-602.
54. Conry RM, Khazaeli MB, Saleh MN. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic anti gen in metastatic adenocarcinomas: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5: 2330-7.
55. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18: 3964-73.
56. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7: 1181-91.
57. Newman DJ, Cragg GM, Holbeck S, Sausville EA. Natural products as leads to cell cycle pathway targets in cancer chemotherapy, Current Cancer Drug Targets 2002; 2: 279-308.
58. Cragg GM, Kingston DGI, Newman DJ. Anticancer Agents from Natural Products. Boca Raton, Florida 2005: Taylor and Francis.
59. Singh OP, Nehru RM. Nanotechnology and cancer treatment. Asian J Exp Sci 2008; 22: 45-50.
60. Pal SK, Mittal B. Fight against cancer in countries with limited resources: The Post-genomic era scenario. Asian Pacific J Cancer Prev 2004; 5: 328-33.
61. De la Chapelle A. Has gene detection benefited the cancer patient? Proc. 10th International Congress Human Genetics 2001, Austria, 63.
62. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278: 1064-8.
63. Fidler IJ, Ellis LE. Chemotherapeutic drugs-more really is not better. Nature Med 2000; 6: 500-2.